Evidence map›Paper›PMID 19533054›Full record

ArticleMedizinische Klinik (Munich, Germany : 1983)2009

[Methicillin-resistant Staphylococcus aureus (MRSA) infections. Epidemiology, diagnostics, therapy, and prevention].

Peter Heeg, Klaus Schröppel

Abstract read
PubMed Publisher
In one paragraph

Article in Medizinische Klinik (Munich, Germany : 1983), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [Epidemiology of and preventive measures for multiresistant pathogens].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2010
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Peter HeegInstitut für Medizinische Mikrobiologie und Hygiene, Universitätsklinikum Tübingen, Elfriede-Aulhorn-Strasse 6, 72076, Tübingen, Germany. peter.heeg@med.uni-tuebingen.de
Klaus Schröppel

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increasing number of complicated soft-tissue or invasive infections caused by methicillin-resistant Staphylococcus aureus (MRSA) is a frequent reason for elaborate treatment regimens. Unidentified MRSA carriers may be the origin of endemic spread to other patients and medical staff. Recently, community-associated cMRSA with particular virulence factors were isolated from persons without the typical history of hospital contacts. Molecular tools for the timely detection of the mecA resistance gene for the identification of MRSA in medical test specimens have become a standard approach in MRSA-related diagnostic procedures. The actual therapy of MRSA infections requires consideration of both the appropriate spectrum of activity and the adequate pharmacological properties of a chosen antimicrobial. Preventive strategies rely on the consistent application of standard hygiene precautions, which have to be supplemented with increased barriers for the isolation of identified MRSA patients.

Indexed as

Methicillin-Resistant Staphylococcus aureusAnimalsBacterial ProteinsBacteriological TechniquesCarrier StateCommunity-Acquired InfectionsCross InfectionCross-Sectional StudiesGermanyHumansIncidencePenicillin-Binding ProteinsRisk FactorsStaphylococcal InfectionsUniversal PrecautionsBacterial ProteinsmecA protein, Staphylococcus aureusPenicillin-Binding Proteins

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.